

ABSTRACT OF THE DISCLOSURE

A medicament for the protection against thrombotic diseases is described that contains an active ~~principle~~ principal which induces irreversible inactivation or degradation of the collagen receptor on thrombocytes. Antibodies, especially the humanized monoclonal antibody JAQ1, are the preferred active principle. Further, a diagnostic agent for the determination of the expression rate of the collagen receptor GPVI is disclosed which contains the labeled monoclonal or polyclonal antibody directed against the GPVI epitope, preferably as defined by JAQ1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com